3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
2
Phase 1/2
2
Phase 1
2
Phase EARLY_PHASE1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
141
Other hematologic neoplasm
109
Plasma cell
62
CNS
37
Sarcoma
27
Gynecologic
27
Thoracic
21
Gastrointestinal
19
Myeloid
18
Dermatologic
12
Head & Neck
11
Genitourinary
11
Breast
11
Endocrine
2
Classical hematology
2
Other solid neoplasm
1
NET
1
Conditions
Neuroendocrine Tumors
43
Carcinoma, Neuroendocrine
22
Small Cell Lung Carcinoma
13
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
11
Sarcoma
10
Lung Neoplasms
9
Thyroid Carcinoma, Anaplastic
7
Thyroid Cancer, Papillary
7
Stomach Neoplasms
7
Pheochromocytoma
7
Paraganglioma
7
Head and Neck Neoplasms
7
Gastro-enteropancreatic neuroendocrine tumor
7
Carcinoid Tumor
7
Thyroid Neoplasms
6
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Ovarian Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Thyroid Diseases
4
Thoracic Neoplasms
4
Respiratory Tract Neoplasms
4
Respiratory Tract Diseases
4
Prostatic Neoplasms
4
Neuroblastoma
4
Neoplasms by Site
4
Multiple Endocrine Neoplasia Type 1
4
Lung Diseases
4
Interventions
olaparib
1
lutetium Lu 177 dotatate
1
entrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
Endocrine
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA